TerraPower Isotopes and PanTera, supported by IRE, Expand Collaboration to Boost Global Actinium-225 Supply

BELLEVUE, WASHINGTON - May 27, 2026 - TerraPower Isotopes (TPI), part of TerraPower, a nuclear innovation company that advances transformative technologies across both energy and healthcare, and PanTera, an innovative producer scaling the supply of vital medical radionuclides, announced an expansion of their ongoing collaboration that will increase Actinium-225 (Ac-225) production capacity in Belgium. The Institut des Radioéléments (IRE), a world leader in the production of medical radionuclides, will host and operate PanTera's new Ac-225 production line, and TPI will provide additional starting material for the expanded production efforts.

"Expanding our collaboration with PanTera represents a defining moment for TerraPower Isotopes, patients and the broader nuclear medicine ecosystem," said Scott Claunch, president at TerraPower Isotopes. "Reliable, scalable actinium-225 supply is the foundation upon which the next generation of life-changing targeted alpha therapies will be built. Our team is increasing capacity in the United States with expansions of our Everett laboratory and our new facility under construction in Philadelphia; and we are thrilled to be supporting new European production capacity with strong counterparts to ultimately enable promising therapies reach patients as quickly as possible."

"The demand from clients for dependable cGMP-compliant Ac-225 is outpacing projections and needs to be robust against interruptions in the production, and this expansion is our joint answer to that market signal," said Christophe Malice, CBO at PanTera. "By distributing our production activity across two different production plants in Belgium (Mol and Fleurus), we enable supply resilience while maintaining the rigorous quality standards our customers depend on. Critically, all material produced under this expanded network will continue to be supplied under our existing Drug Master File and IMPD-Q only applications, providing a single regulatory reference that simplifies our customers' own submissions and accelerates their timelines."

"This collaboration reinforces Belgium's position at the forefront of European radioisotope production and CDMO services," said Erich Kollegger, CEO at IRE. "IRE has been a cornerstone of nuclear medicine supply for decades, and our involvement in this expanded Ac-225 network is a natural extension of that mission. We are proud to contribute to an infrastructure that will serve global patients for years to come and extremely thankful toward TPI and PanTera for their trust and for offering us to support this collaboration."

Building on an existing weekly production program that is already delivering highly pure Ac-225 to drug developers, this additional starting material from TPI will allow Pantera to significantly scale supply capacity through two complementary initiatives:

• Expand the current production and weekly output at the Mol, Belgium facility, reinforcing the current Good Manufacturing Practices (cGMP) supply base; and
• Launch a new Ac-225 production facility located at IRE, strengthening geographic and operational resilience.

Together, these two initiatives will grow PanTera's total cGMP Ac-225 capacity by more than 200 percent, creating the critical mass of supply required to support later stage human clinical trials and early commercial-stage radiopharmaceutical programs for drug developers. The new production line at IRE will be fully operational within the next 18 months by leveraging on the expertise, organisation and infrastructure of IRE, as a seasoned manufacturer of cGMP radionuclides for diagnostic and therapeutic applications.

Both TPI and PanTera are also further expanding manufacturing capacity at this crucial moment of growth in the development of targeted alpha therapies. TPI is actively expanding its current Everett, Washington (USA) laboratory, and constructing a new cGMP facility in Philadelphia, Pennsylvania (USA) to increase the global Ac-225 production capacity twentyfold. PanTera is currently constructing its photonuclear production plant in Mol (Belgium).

These production routes of TerraPower and PanTera are anticipated to provide the industry with credible, diversified supply chains capable of supporting approved commercial products at scale.

About TerraPower Isotopes
TerraPower Isotopes (TPI) is a mission-driven organization, founded by Bill Gates and a group of like-minded visionaries to solve global challenges using nuclear science. The TPI team applies innovative expertise and proven development methods to providing a secure isotope supply chain for targeted alpha therapies development. TerraPower Isotopes is increasing global access to actinium-225, supporting industry by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential.

About TerraPower
TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. Learn more at terrapower.com.

About PanTera
PanTera originated as a joint venture between IBA and SCK CEN, established to secure the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope for targeted cancer therapies. With a Series A funding of €95.6 million and all necessary building blocks available, PanTera is ideally positioned to develop cutting-edge production capabilities to enable the accessibility of innovative cancer treatments based on Ac-225.

PanTera's production strategy is built on two complementary approaches: an Early Supply production leveraging Thorium-229 decay, which is providing Ac-225 since May 2025, and a Commercial Supply production utilizing the Ra-226 photonuclear reaction to enable large-scale commercial production by 2028. These initiatives ensure a sustainable and scalable supply chain to meet the growing global demand for Ac-225. Learn more at www.pantera-life.com

About IRE
The National Institute for Radioelements (IRE) is a public-interest foundation whose core activity is the production of radioisotopes for diagnostic and therapeutic applications in nuclear medicine. IRE is the world leader in the production of Molybdenum-99 and Iodine-131, two of the most widely used isotopes in nuclear medicine for a broad range of diagnostic and therapeutic procedures.

IRE is also expanding its CDMO capabilities, with new state-of-the-art production lines becoming available soon to support partners from early development to commercial manufacturing.

Founded in 2010, IRE ELiT is IRE's innovation-focused subsidiary dedicated to the end-to-end development of radiopharmaceutical medicinal products for imaging and cancer treatment. Together, IRE and IRE ELiT employ more than 280 people. Learn more at www.ire.eu

Press contacts:
TerraPower - [email protected]
Pantera - [email protected]
IRE - [email protected]